Johnson & Johnson $JNJ Stake Cut by Trinity Legacy Partners LLC

Trinity Legacy Partners LLC reduced its holdings in Johnson & Johnson (NYSE:JNJ) by 41.7% in the 2nd quarter, Holdings Channel reports. The fund owned 36,630 shares of the company’s stock after selling 26,249 shares during the period. Johnson & Johnson makes up about 1.5% of Trinity Legacy Partners LLC’s portfolio, making the stock its 23rd biggest position. Trinity Legacy Partners LLC’s holdings in Johnson & Johnson were worth $6,036,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the business. Hilltop National Bank purchased a new stake in Johnson & Johnson in the 2nd quarter worth about $1,817,000. Triad Wealth Partners LLC grew its stake in shares of Johnson & Johnson by 72.0% in the 2nd quarter. Triad Wealth Partners LLC now owns 6,369 shares of the company’s stock valued at $973,000 after buying an additional 2,667 shares in the last quarter. Red Mountain Financial LLC grew its stake in shares of Johnson & Johnson by 32.9% in the 2nd quarter. Red Mountain Financial LLC now owns 2,071 shares of the company’s stock valued at $303,000 after buying an additional 513 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Johnson & Johnson by 7.3% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 425,395 shares of the company’s stock valued at $64,979,000 after buying an additional 28,828 shares in the last quarter. Finally, Tower View Wealth Management LLC grew its stake in shares of Johnson & Johnson by 625.3% in the 2nd quarter. Tower View Wealth Management LLC now owns 1,661 shares of the company’s stock valued at $254,000 after buying an additional 1,432 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Performance

JNJ opened at $188.51 on Friday. The firm has a market capitalization of $453.98 billion, a P/E ratio of 20.16, a price-to-earnings-growth ratio of 2.40 and a beta of 0.40. The stock’s 50 day moving average price is $176.18 and its two-hundred day moving average price is $162.83. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $189.78.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.68 by $0.09. The firm had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The company’s revenue was up 5.8% on a year-over-year basis. During the same quarter last year, the firm posted $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, equities analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were given a $1.30 dividend. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.8%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 55.61%.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

JNJ has been the subject of several recent research reports. Morgan Stanley boosted their price target on Johnson & Johnson from $171.00 to $176.00 and gave the company an “equal weight” rating in a research note on Thursday, July 17th. Wall Street Zen raised Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Saturday, September 13th. Bank of America increased their price objective on Johnson & Johnson from $175.00 to $198.00 and gave the company a “neutral” rating in a report on Friday. Citigroup increased their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the company a “buy” rating in a report on Thursday, August 21st. Finally, Erste Group Bank raised Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Wednesday, July 23rd. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $188.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.